This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 111.2 kDa. As a result of glycosylation, the protein migrates as 140-160 kDa under reducing (R) condition, and 280-320 kDa under non-reducing (NR) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human VEGF R3, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) was more than 85% and the molecular weight of this protein is around 260-320 kDa verified by SEC-MALS.
Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 19.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Human VEGF-C, His Tag (Cat. No. VEC-H4225) captured on CM5 Chip via anti-His antibody can bind Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) with an affinity constant of 41.1 pM as determined in SPR assay (Biacore T200) (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.